Marilena Vrana Reflects on A Year of Growth, Gratitude, and Collective Strength
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”As the year draws to a close, it offers a natural moment to step back and acknowledge the growth, challenges, and progress that have shaped these past months.
Transitions in leadership are rarely seamless, and stepping into this new role mid-year came with a steep learning curve.
Yet through the transition came a clear lesson: leadership isn’t about having all the answers, but about creating the conditions where collaboration, curiosity, and courage can truly thrive.
This year showed again that resilience is built through collective effort.
The challenges we faced became catalysts for reimagining what’s possible, and our achievements became shared wins that strengthened the sense of purpose across the team, our membership, and the broader community of plasma and plasma-derived medicines.
What has truly fueled me throughout the year is the unwavering dedication of the PPTA Europe staff and members.
Your commitment to the mission, your integrity, and your persistence have shaped not only the milestones we reached, but also the “one-team” culture that continues to take root – grounded in trust, transparency, and shared responsibility.
As the year ends, I am deeply grateful for every colleague, partner, and supporter who contributed to this progress.
Thank you for your patience as I found my footing, for the feedback that sharpened our focus, and for the belief in what we’re building together.
In many ways, I’ve grown not just as a leader, but as a listener, a learner, and a teammate.
The year ahead holds promise with new opportunities, renewed momentum, and continued collaboration.
Here’s to building on this foundation together in the coming year, with purpose and optimism.”
Stay updated with Hemostasis Today.
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion
-
Jun 6, 2026, 17:37Intissar Haddiya: Can Low-Dose Rivaroxaban Improve Cardiovascular Outcomes in Patients with Advanced CKD?
-
Jun 6, 2026, 17:34Stanley Anokye: From Microcytes and Macrocytes to Target Cells
-
Jun 6, 2026, 16:53Leonardo Roever: Can a Simple Cholesterol Ratio Predict Post-Stroke Depression?
-
Jun 6, 2026, 16:21Abdulkader Jamal Eddin: ABO Blood Group, COVID-19 and Early Respiratory Outcomes in Acute PE
-
Jun 6, 2026, 15:26Yuying Zhang: Grateful to Present on CD44 as A Potential Plasma-Independent Alternative to IVIG in ITP
-
Jun 6, 2026, 15:16Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
-
Jun 6, 2026, 15:14Julianne Chong: Components of Antithrombotic Stewardship Programs from an International Perspective
-
Jun 6, 2026, 15:13Vincent Ten Cate: The Largest Blood-Based EWAS of Atherosclerosis to Date